These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24712857)

  • 1. Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.
    Busch A; Zeh D; Janzen V; Mügge LO; Wolf D; Fingerhut L; Hahn-Ast C; Maurer O; Brossart P; von Lilienfeld-Toal M
    Clin Exp Immunol; 2014 Aug; 177(2):439-53. PubMed ID: 24712857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
    Lee SE; Lim JY; Ryu DB; Kim TW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim M; Min CK
    Cancer Immunol Immunother; 2016 Aug; 65(8):983-94. PubMed ID: 27342591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Properties of thalidomide and its analogues: implications for anticancer therapy.
    Teo SK
    AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow myeloid cells in regulation of multiple myeloma progression.
    Herlihy SE; Lin C; Nefedova Y
    Cancer Immunol Immunother; 2017 Aug; 66(8):1007-1014. PubMed ID: 28378067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in immune cell populations following KappaMab, lenalidomide and low-dose dexamethasone treatment in multiple myeloma.
    Norton SE; Khong T; Ramachandran M; Highton AJ; Ward-Hartstonge KA; Shortt J; Spencer A; Kemp RA
    Clin Transl Immunology; 2023; 12(12):e1478. PubMed ID: 38034081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
    Sklavenitis-Pistofidis R; Aranha MP; Redd RA; Baginska J; Haradhvala NJ; Hallisey M; Dutta AK; Savell A; Varmeh S; Heilpern-Mallory D; Ujwary S; Zavidij O; Aguet F; Su NK; Lightbody ED; Bustoros M; Tahri S; Mouhieddine TH; Wu T; Flechon L; Anand S; Rosenblatt JM; Zonder J; Vredenburgh JJ; Boruchov A; Bhutani M; Usmani SZ; Matous J; Yee AJ; Jakubowiak A; Laubach J; Manier S; Nadeem O; Richardson P; Badros AZ; Mateos MV; Trippa L; Getz G; Ghobrial IM
    Cancer Cell; 2022 Nov; 40(11):1358-1373.e8. PubMed ID: 36379208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Immunomodulatory Effects of Honey and Associated Flavonoids in Cancer.
    Masad RJ; Haneefa SM; Mohamed YA; Al-Sbiei A; Bashir G; Fernandez-Cabezudo MJ; Al-Ramadi BK
    Nutrients; 2021 Apr; 13(4):. PubMed ID: 33924384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
    Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
    Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
    De Keersmaecker B; Fostier K; Corthals J; Wilgenhof S; Heirman C; Aerts JL; Thielemans K; Schots R
    Cancer Immunol Immunother; 2014 Oct; 63(10):1023-36. PubMed ID: 24947180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?
    Paiva B; Puig N; García-Sanz R; San Miguel JF;
    Clin Cancer Res; 2015 May; 21(9):2001-8. PubMed ID: 25754350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma.
    Brissot E; Clavert A; Blin N; Roland V; Guillaume T; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Gaugler B; Moreau P; Mohty M
    Leukemia; 2015 Oct; 29(10):2098-100. PubMed ID: 25748683
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.
    Wang Z; Zhang L; Wang H; Xiong S; Li Y; Tao Q; Xiao W; Qin H; Wang Y; Zhai Z
    Cancer Immunol Immunother; 2015 Mar; 64(3):389-99. PubMed ID: 25548095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
    Szmania S; Lapteva N; Garg T; Greenway A; Lingo J; Nair B; Stone K; Woods E; Khan J; Stivers J; Panozzo S; Campana D; Bellamy WT; Robbins M; Epstein J; Yaccoby S; Waheed S; Gee A; Cottler-Fox M; Rooney C; Barlogie B; van Rhee F
    J Immunother; 2015 Jan; 38(1):24-36. PubMed ID: 25415285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma.
    Usmani SZ; Zhang Q; Stratton K; Qu P; Yaccoby S; Hansen E; Steward D; Panozzo S; Petty N; Hoering A; Waheed S; Van Rhee F; Crowley J; Barlogie B
    Leukemia; 2014 Dec; 28(12):2413-5. PubMed ID: 25151956
    [No Abstract]   [Full Text] [Related]  

  • 15. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.
    Alsina M; Becker PS; Zhong X; Adams A; Hari P; Rowley S; Stadtmauer EA; Vesole DH; Logan B; Weisdorf D; Qazilbash M; Popplewell LL; McClune B; Bensinger W; Riches M; Giralt SA; Pasquini MC;
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1183-9. PubMed ID: 24769014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.
    Kuwahara-Ota S; Shimura Y; Steinebach C; Isa R; Yamaguchi J; Nishiyama D; Fujibayashi Y; Takimoto-Shimomura T; Mizuno Y; Matsumura-Kimoto Y; Tsukamoto T; Chinen Y; Kobayashi T; Horiike S; Taniwaki M; Gütschow M; Kuroda J
    Br J Haematol; 2020 Dec; 191(5):784-795. PubMed ID: 32558939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
    Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
    Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma.
    Amatangelo M; Flynt E; Stong N; Ray P; Van Oekelen O; Wang M; Ortiz M; Maciag P; Peluso T; Parekh S; van de Donk NWCJ; Lonial S; Thakurta A
    Cell Rep Med; 2024 Jun; 5(6):101571. PubMed ID: 38776914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death.
    Ray A; Du T; Wan X; Song Y; Pillai SC; Musa MA; Fang T; Moore J; Blank B; Du X; Chen X; Warne R; Sutimantanapi D; Lui F; Zavorotinskaya T; Colas C; Friedman L; Junttila MR; Chauhan D; Anderson KC
    Blood Cancer J; 2024 Apr; 14(1):58. PubMed ID: 38594241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The recent progress of myeloid-derived suppressor cell and its targeted therapies in cancers.
    Ren R; Xiong C; Ma R; Wang Y; Yue T; Yu J; Shao B
    MedComm (2020); 2023 Aug; 4(4):e323. PubMed ID: 37547175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.